in september 2012 , european society for medical oncology ( esmo ) 2012 congress in vienna , austria we announced preliminary data from the physician initiated clinical trial of th-302 in combination with bevacizumab in patients with recurrent glioblastoma . in february of 2012 we reported top-line results from the randomized and controlled phase 2 trial of th-302 plus gemcitabine in patients with pancreatic cancer ( 404 trial ) . the median progression-free survival progression free survival was 5.6 months for patients treated with gemcitabine in combination with th-302 at 240 mg/m2 and 340 mg/m2 compared to 3.6 months for patients treated with gemcitabine alone . the progression free survival hazard ratio comparing the th-302 combination to gemcitabine alone was 0.61 ( 95 % confidence 46 interval : 0.430.87 ) which was highly statistically significant ( p = 0.005 ) and represented a 63 % improvement in progression free survival . the response rate in the combination arms was 22 % compared to 12 % in the gemcitabine alone group . results also demonstrated greater efficacy in the higher th-302 dose group compared to the lower dose group . the combination had a safety profile that was consistent with our prior study of this combination regimen . as in that study , skin and mucosal toxicities related to th-302 were dose dependent but not dose limiting . in april 2012 , we provided detailed results from our 404 trial at the american association of cancer research ( aacr ) annual meeting including results for each of the 240 mg/m2 and 340 mg/m2 th-302 combination arms . the median progression free survival was 6.0 months in the 340 mg/m2 group . the response rate was 27 % in the 340 mg/m2 group . a similar dose dependency was reported in serum ca19-9 levels . there was greater drug exposure in the combination groups with a median of 4 cycles received with gemcitabine alone compared with 5 cycles in the 240 mg/m2 group and 6 cycles in the 340 mg/m2 group . the combination safety profile was consistent with the prior study of this combination regimen . as in that study , skin and mucosal toxicities were less than what had been seen at the single-agent maximum tolerated dose of th-302 , which was previously established at 575 mg/m2 . the incidence of grade 3/4 thrombocytopenia and grade 3/4 neutropenia was significantly higher in the combination arms and highest in the 340 mg/m2 group . discontinuations for adverse events were lowest however in the 340 mg/m2 group . in september 2012 , at esmo 2012 congress , updated results were presented confirming a significant improvement ( p=0.008 ) in progression free survival . the updated progression free survival hazard ratio comparing the th-302 combinations to gemcitabine alone was 0.64 ( 95 % confidence interval : 0.450.89 ) . this was associated with a 2.4-month increase in median progression free survival for patients receiving th-302 340 mg/m 2 . new findings from the phase 2b trial were presented including an analysis of overall survival , which was a secondary endpoint of the study . this analysis indicated that patients treated with gemcitabine alone had a median overall survival of 6.9 months compared with 9.2 months for patients treated with 340 mg/m2 th-302 plus gemcitabine ( hr : 0.955 , 95 % ci : 0.67-1.37 , p=0.800 ) and 8.7 months for patients treated with 240 mg/m2 th-302 plus gemcitabine ( hr : 0.960 , 95 % ci : 0.67-1.38 , p=0.827 ) . while not statistically significant , the improvement in median overall survival is consistent with the improvement in median progression free survival reported previously . the trial was not designed to detect a statistically significant improvement in overall survival and included a cross-over component . patients receiving gemcitabine alone who crossed over to receive gemcitabine plus th-302 upon disease progression contributed to an increase in survival of the control arm . th-302 continued to demonstrate a safety profile consistent with what had been previously reported at aacr . the most common adverse events were fatigue , nausea , constipation and peripheral edema , and were similar across groups . skin and mucosal toxicities and myelosuppression were the most common adverse events related to th-302 , were mostly grade 1 and 2 , and did not result in increases in treatment discontinuation . adverse events leading to discontinuation of study treatment as well as serious adverse events were balanced across all treatment arms . grade 3/4/5 adverse events were generally below 10 % . in december 2012 , merck kgaa opened maestro a global phase 3 trial of th-302 plus gemcitabine in patients with pancreatic cancer . maestro stands for th-302 in the treatment of metastatic or unresectable pancreatic adenocarcinoma . in 2011 , we presented updated top-line results from our phase 1/2 combination therapy in patients with soft tissue sarcoma treated with doxorubicin plus th-302 at the maximum tolerated dose of 300 mg/m 2 ( 403 trial ) . we also provided additional data from the maintenance component as well as an update on the overall efficacy of the phase 2 component of the 403 trial at the 17 th ctos annual meeting in november 2012. in february 2011 , we reached agreement with the fda on the design and planned analysis of a pivotal phase 3 trial in patients with soft tissue sarcoma ( 406 trial ) . as part of the special protocol assessment ( spa ) submission , the fda agreed that the design and planned analysis of the proposed phase 3 trial adequately addresses the objectives necessary to support a regulatory submission . story_separator_special_tag the number of shares we are able to sell under this arrangement will be limited in practice based on the trading volume of our common stock . as of december 31 , 2010 we had not sold any stock pursuant to the sales agreement . for the year ended december 31 , 2011 , we sold an aggregate of 971,037 shares of our common stock at an average price of $ 2.66 pursuant to the sales agreement . net proceeds from the sale of stock in 2011 were $ 2.3 million . the sales of the stock did not result in an adjustment to the exercise price of certain of our outstanding warrants . pursuant to an amendment to the at the market issuance sales agreement and a prospectus supplement we filed on january 20 , 2012 and pursuant to a new registration statement filed with the securities and exchange commission , we may sell shares of our common stock having an aggregate offering price of up to $ 15.0 million from time to time through mlv as our sales agent on the terms and conditions described above . 53 during year ended december 31 , 2012 , we sold 2,022,144 shares of our common stock at an average price of $ 6.29 pursuant to the sales agreement . net proceeds from the sale of stock were $ 12.3 million . the sale of stock did not result in an adjustment to the exercise price of certain of our outstanding warrants . license and development agreements on february 3 , 2012 , we entered into a global license and co-development agreement with merck kgaa , of darmstadt , germany , to co-develop and commercialize th-302 , our small molecule hypoxia-targeted drug . under the terms of the agreement , merck will receive co-development rights , exclusive global commercialization rights and will provide us an option to co-commercialize th-302 in the united states . in exchange , we received an upfront payment of $ 25 million and received another $ 72.5 million in development milestones , including $ 42.5 million subsequent to december 31 , 2012. we can earn additional potential milestone payments of $ 452.5 million , comprised of $ 112.5 million in regulatory and development milestones and $ 340 million in sales-based milestones . in the united states , we will have primary responsibility for development of th-302 in the soft tissue sarcoma indication . we with merck kgaa will jointly develop th-302 in all other cancer indications being pursued . merck kgaa will pay 70 % of worldwide development costs for th-302 . subject to fda approval in the united states , merck kgaa will initially be responsible for commercialization of th-302 while we will receive a tiered , double-digit royalty on sales . under the royalty-bearing portion of the agreement , we retain the option to co-promote th-302 in the united states . additionally , we retain the option to co-commercialize th-302 upon the achievement of certain sales or regulatory milestones , allowing us to participate in up to 50 % of the profits in the united states depending on total sales . outside of the united states , merck kgaa will be solely responsible for the commercialization of th-302 while we will receive a tiered , double-digit royalty on sales in these territories . the agreement became effective on march 12 , 2012 , upon termination of the applicable waiting period under the hart-scott-rodino antitrust improvements act of 1976. the agreement will continue on a country-by-country basis until the later of the last to expire patent covering th-302 in such country or ten years following the commercial launch of a product containing th-302 in such country , unless terminated earlier . merck has the right to terminate the agreement after the achievement of certain milestones , and each party has the right to terminate the agreement following uncured material breach by the other party . on october 14 , 2009 , we entered into an exclusive license agreement with eleison pharmaceuticals , inc. ( eleison ) . pursuant to the agreement we granted eleison exclusive worldwide rights to develop and commercialize glufosfamide for the treatment of cancer in humans and animals , and certain other uses . under the agreement , eleison is responsible for the development , manufacturing and marketing of glufosfamide . eleison and threshold will share equally in the profits of commercialization , if the further clinical development of glufosfamide leads to regulatory approval and marketing . eleison will pay us 50 % of its profits from commercialization on a quarterly basis , beginning on the date of first commercial sale , if any . eleison has the right to sublicense some or all of its rights under the agreement , and will pay us 50 % of amounts received under any sublicenses , including , without limitation , any royalty payments , license fee payments , milestone payments and payments for any equity or debt purchases by a sublicensee , within 30 days of the receipt of any such amounts or payments by eleison . eleison will bear all costs associated with development , commercialization and patent prosecution , and will control product development and commercialization . in addition , eleison will be responsible for all royalty and milestone payments due under the baxter license and medibic development agreement discussed below . the agreement contemplates that eleison , to satisfy its diligence obligations , will raise sufficient funds to commence clinical development activities with glufosfamide . 54 off-balance sheet arrangements as of december 31 , 2012 , 2011 and 2010 , we did not have any relationships with unconsolidated entities or financial partnerships , such as entities often referred to as structured finance or special purpose entities , which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes . in addition , we do not engage in trading activities involving non-exchange traded

liquidity and capital resources we have incurred net losses of $ 323.3 million since inception through december 31 , 2012. we have not generated and do not expect to generate revenue from sales of product candidates in the near term . since our inception , we funded our operations primarily through private placements and public offerings of equity securities and through payments received under our license and co-development agreement with merck kgaa . during the year ended december 31 , 2012 , we sold an aggregate of approximately 2.0 million shares of common stock under our at the market stock issuance facility for net proceeds of $ 12.3 million , and we received approximately $ 8.8 million from the exercise of warrants to purchase approximately 4.7 million shares of common stock . during the year ended december 31 , 2011 we sold approximately 1.0 million shares of our common stock at an average price of $ 2.66 under our at the market stock issuance facility , for net proceeds of $ 2.3 million . in march 2011 , we sold to certain investors an aggregate of approximately 14.3 million shares of our common stock for a purchase price equal to $ 2.05 per share and , for a purchase price equal to $ 0.05 per share , warrants exercisable for a total of approximately 5.7 million shares of our common stock for aggregate gross proceeds equal to $ 30.1 million in connection with the offering . the warrants have an exercise price equal to $ 2.46 per share . net proceeds generated from the offering were approximately $ 27.8 million , which includes underwriter discounts and offering costs . 51 on february 3 , 2012 , we entered into an agreement with merck kgaa and to date have received upfront and milestone payments of $ 97.5 million , including $ 42.5 million in milestone payments received subsequent to december 31 , 2012. we could also receive an additional $ 12.5 million in a potential milestone payment in 2013.


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have incurred net losses of $ 323.3 million since inception through december 31 , 2012. we have not generated and do not expect to generate revenue from sales of product candidates in the near term . since our inception , we funded our operations primarily through private placements and public offerings of equity securities and through payments received under our license and co-development agreement with merck kgaa . during the year ended december 31 , 2012 , we sold an aggregate of approximately 2.0 million shares of common stock under our at the market stock issuance facility for net proceeds of $ 12.3 million , and we received approximately $ 8.8 million from the exercise of warrants to purchase approximately 4.7 million shares of common stock . during the year ended december 31 , 2011 we sold approximately 1.0 million shares of our common stock at an average price of $ 2.66 under our at the market stock issuance facility , for net proceeds of $ 2.3 million . in march 2011 , we sold to certain investors an aggregate of approximately 14.3 million shares of our common stock for a purchase price equal to $ 2.05 per share and , for a purchase price equal to $ 0.05 per share , warrants exercisable for a total of approximately 5.7 million shares of our common stock for aggregate gross proceeds equal to $ 30.1 million in connection with the offering . the warrants have an exercise price equal to $ 2.46 per share . net proceeds generated from the offering were approximately $ 27.8 million , which includes underwriter discounts and offering costs . 51 on february 3 , 2012 , we entered into an agreement with merck kgaa and to date have received upfront and milestone payments of $ 97.5 million , including $ 42.5 million in milestone payments received subsequent to december 31 , 2012. we could also receive an additional $ 12.5 million in a potential milestone payment in 2013.
```    
 Suspicious Activity Report : in september 2012 , european society for medical oncology ( esmo ) 2012 congress in vienna , austria we announced preliminary data from the physician initiated clinical trial of th-302 in combination with bevacizumab in patients with recurrent glioblastoma . in february of 2012 we reported top-line results from the randomized and controlled phase 2 trial of th-302 plus gemcitabine in patients with pancreatic cancer ( 404 trial ) . the median progression-free survival progression free survival was 5.6 months for patients treated with gemcitabine in combination with th-302 at 240 mg/m2 and 340 mg/m2 compared to 3.6 months for patients treated with gemcitabine alone . the progression free survival hazard ratio comparing the th-302 combination to gemcitabine alone was 0.61 ( 95 % confidence 46 interval : 0.430.87 ) which was highly statistically significant ( p = 0.005 ) and represented a 63 % improvement in progression free survival . the response rate in the combination arms was 22 % compared to 12 % in the gemcitabine alone group . results also demonstrated greater efficacy in the higher th-302 dose group compared to the lower dose group . the combination had a safety profile that was consistent with our prior study of this combination regimen . as in that study , skin and mucosal toxicities related to th-302 were dose dependent but not dose limiting . in april 2012 , we provided detailed results from our 404 trial at the american association of cancer research ( aacr ) annual meeting including results for each of the 240 mg/m2 and 340 mg/m2 th-302 combination arms . the median progression free survival was 6.0 months in the 340 mg/m2 group . the response rate was 27 % in the 340 mg/m2 group . a similar dose dependency was reported in serum ca19-9 levels . there was greater drug exposure in the combination groups with a median of 4 cycles received with gemcitabine alone compared with 5 cycles in the 240 mg/m2 group and 6 cycles in the 340 mg/m2 group . the combination safety profile was consistent with the prior study of this combination regimen . as in that study , skin and mucosal toxicities were less than what had been seen at the single-agent maximum tolerated dose of th-302 , which was previously established at 575 mg/m2 . the incidence of grade 3/4 thrombocytopenia and grade 3/4 neutropenia was significantly higher in the combination arms and highest in the 340 mg/m2 group . discontinuations for adverse events were lowest however in the 340 mg/m2 group . in september 2012 , at esmo 2012 congress , updated results were presented confirming a significant improvement ( p=0.008 ) in progression free survival . the updated progression free survival hazard ratio comparing the th-302 combinations to gemcitabine alone was 0.64 ( 95 % confidence interval : 0.450.89 ) . this was associated with a 2.4-month increase in median progression free survival for patients receiving th-302 340 mg/m 2 . new findings from the phase 2b trial were presented including an analysis of overall survival , which was a secondary endpoint of the study . this analysis indicated that patients treated with gemcitabine alone had a median overall survival of 6.9 months compared with 9.2 months for patients treated with 340 mg/m2 th-302 plus gemcitabine ( hr : 0.955 , 95 % ci : 0.67-1.37 , p=0.800 ) and 8.7 months for patients treated with 240 mg/m2 th-302 plus gemcitabine ( hr : 0.960 , 95 % ci : 0.67-1.38 , p=0.827 ) . while not statistically significant , the improvement in median overall survival is consistent with the improvement in median progression free survival reported previously . the trial was not designed to detect a statistically significant improvement in overall survival and included a cross-over component . patients receiving gemcitabine alone who crossed over to receive gemcitabine plus th-302 upon disease progression contributed to an increase in survival of the control arm . th-302 continued to demonstrate a safety profile consistent with what had been previously reported at aacr . the most common adverse events were fatigue , nausea , constipation and peripheral edema , and were similar across groups . skin and mucosal toxicities and myelosuppression were the most common adverse events related to th-302 , were mostly grade 1 and 2 , and did not result in increases in treatment discontinuation . adverse events leading to discontinuation of study treatment as well as serious adverse events were balanced across all treatment arms . grade 3/4/5 adverse events were generally below 10 % . in december 2012 , merck kgaa opened maestro a global phase 3 trial of th-302 plus gemcitabine in patients with pancreatic cancer . maestro stands for th-302 in the treatment of metastatic or unresectable pancreatic adenocarcinoma . in 2011 , we presented updated top-line results from our phase 1/2 combination therapy in patients with soft tissue sarcoma treated with doxorubicin plus th-302 at the maximum tolerated dose of 300 mg/m 2 ( 403 trial ) . we also provided additional data from the maintenance component as well as an update on the overall efficacy of the phase 2 component of the 403 trial at the 17 th ctos annual meeting in november 2012. in february 2011 , we reached agreement with the fda on the design and planned analysis of a pivotal phase 3 trial in patients with soft tissue sarcoma ( 406 trial ) . as part of the special protocol assessment ( spa ) submission , the fda agreed that the design and planned analysis of the proposed phase 3 trial adequately addresses the objectives necessary to support a regulatory submission . story_separator_special_tag the number of shares we are able to sell under this arrangement will be limited in practice based on the trading volume of our common stock . as of december 31 , 2010 we had not sold any stock pursuant to the sales agreement . for the year ended december 31 , 2011 , we sold an aggregate of 971,037 shares of our common stock at an average price of $ 2.66 pursuant to the sales agreement . net proceeds from the sale of stock in 2011 were $ 2.3 million . the sales of the stock did not result in an adjustment to the exercise price of certain of our outstanding warrants . pursuant to an amendment to the at the market issuance sales agreement and a prospectus supplement we filed on january 20 , 2012 and pursuant to a new registration statement filed with the securities and exchange commission , we may sell shares of our common stock having an aggregate offering price of up to $ 15.0 million from time to time through mlv as our sales agent on the terms and conditions described above . 53 during year ended december 31 , 2012 , we sold 2,022,144 shares of our common stock at an average price of $ 6.29 pursuant to the sales agreement . net proceeds from the sale of stock were $ 12.3 million . the sale of stock did not result in an adjustment to the exercise price of certain of our outstanding warrants . license and development agreements on february 3 , 2012 , we entered into a global license and co-development agreement with merck kgaa , of darmstadt , germany , to co-develop and commercialize th-302 , our small molecule hypoxia-targeted drug . under the terms of the agreement , merck will receive co-development rights , exclusive global commercialization rights and will provide us an option to co-commercialize th-302 in the united states . in exchange , we received an upfront payment of $ 25 million and received another $ 72.5 million in development milestones , including $ 42.5 million subsequent to december 31 , 2012. we can earn additional potential milestone payments of $ 452.5 million , comprised of $ 112.5 million in regulatory and development milestones and $ 340 million in sales-based milestones . in the united states , we will have primary responsibility for development of th-302 in the soft tissue sarcoma indication . we with merck kgaa will jointly develop th-302 in all other cancer indications being pursued . merck kgaa will pay 70 % of worldwide development costs for th-302 . subject to fda approval in the united states , merck kgaa will initially be responsible for commercialization of th-302 while we will receive a tiered , double-digit royalty on sales . under the royalty-bearing portion of the agreement , we retain the option to co-promote th-302 in the united states . additionally , we retain the option to co-commercialize th-302 upon the achievement of certain sales or regulatory milestones , allowing us to participate in up to 50 % of the profits in the united states depending on total sales . outside of the united states , merck kgaa will be solely responsible for the commercialization of th-302 while we will receive a tiered , double-digit royalty on sales in these territories . the agreement became effective on march 12 , 2012 , upon termination of the applicable waiting period under the hart-scott-rodino antitrust improvements act of 1976. the agreement will continue on a country-by-country basis until the later of the last to expire patent covering th-302 in such country or ten years following the commercial launch of a product containing th-302 in such country , unless terminated earlier . merck has the right to terminate the agreement after the achievement of certain milestones , and each party has the right to terminate the agreement following uncured material breach by the other party . on october 14 , 2009 , we entered into an exclusive license agreement with eleison pharmaceuticals , inc. ( eleison ) . pursuant to the agreement we granted eleison exclusive worldwide rights to develop and commercialize glufosfamide for the treatment of cancer in humans and animals , and certain other uses . under the agreement , eleison is responsible for the development , manufacturing and marketing of glufosfamide . eleison and threshold will share equally in the profits of commercialization , if the further clinical development of glufosfamide leads to regulatory approval and marketing . eleison will pay us 50 % of its profits from commercialization on a quarterly basis , beginning on the date of first commercial sale , if any . eleison has the right to sublicense some or all of its rights under the agreement , and will pay us 50 % of amounts received under any sublicenses , including , without limitation , any royalty payments , license fee payments , milestone payments and payments for any equity or debt purchases by a sublicensee , within 30 days of the receipt of any such amounts or payments by eleison . eleison will bear all costs associated with development , commercialization and patent prosecution , and will control product development and commercialization . in addition , eleison will be responsible for all royalty and milestone payments due under the baxter license and medibic development agreement discussed below . the agreement contemplates that eleison , to satisfy its diligence obligations , will raise sufficient funds to commence clinical development activities with glufosfamide . 54 off-balance sheet arrangements as of december 31 , 2012 , 2011 and 2010 , we did not have any relationships with unconsolidated entities or financial partnerships , such as entities often referred to as structured finance or special purpose entities , which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes . in addition , we do not engage in trading activities involving non-exchange traded

